Clinical Trials on Non-invasive Inflammatory Markers in Russian Federation

Total 12 results

Pfizer
Vicuron Pharmaceuticals

Completed

The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasis

Candidiasis

United States
Pfizer

Completed

Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis

Candidemia

United States, Taiwan, Spain, United Kingdom, Korea, Republic of, Brazil, Greece, Canada, Italy, Russian Federation
Pfizer

Completed

Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study (ICE)

Invasive Candidiasis

Czech Republic, Belgium, Austria, Portugal, Russian Federation, Turkey, Canada, Germany, Italy, United Kingdom, Hungary, France, Slovakia, Denmark, Romania, Netherlands, Poland, Greece, Ukraine
Pfizer

Terminated

An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System

Candidiasis | Fungemia | Neutropenia

Poland, Russian Federation, France, Bosnia and Herzegovina, Italy, Slovakia
Cidara Therapeutics Inc.

Completed

CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension (STRIVE)

Mycoses | Candidemia | Fungemia | Fungal Infection | Invasive Candidiasis

United States, Spain, Belgium, Russian Federation, Greece, Bulgaria, Canada, Hungary, Italy, Romania
Pfizer

Terminated

An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Deep Tissue Infection Due To Candida

Candidiasis | Fungemia

Belgium, United States, Canada, Switzerland, Netherlands, Bulgaria, Portugal, Romania, Russian Federation
Astellas Pharma Inc
Basilea Pharmaceutica

Completed

Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections

Mycoses | Candidemia | Candidiasis, Invasive

Philippines, New Zealand, United States, Spain, Belgium, Canada, Israel, Malaysia, Mexico, Italy, Australia, Germany, Singapore, Hungary, Brazil, Thailand, China, India, Argentina, France, Russian Federation, Chile, Lebanon, South Africa and more
AstraZeneca

Active, not recruiting

Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer (POTOMAC)

Non-muscle-invasive Bladder Cancer

France, Spain, Belgium, Canada, Poland, Germany, Japan, Russian Federation, United Kingdom, Austria, Australia, Netherlands
Janssen Research & Development, LLC

Recruiting

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy (SunRISe-1)

Urinary Bladder Neoplasms

United States, Belgium, Korea, Republic of, Germany, Italy, France, Spain, Canada, United Kingdom, Greece, Japan, Netherlands, Portugal, Australia, Russian Federation, Ukraine
Bristol-Myers Squibb

Terminated

A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (CheckMate 7G8)

Urinary Bladder Neoplasms

United States, Netherlands, Italy, Argentina, Australia, Austria, Brazil, Canada, Chile, France, Germany, Greece, Israel, Japan, Russian Federation, Spain, Sweden
UroGen Pharma Ltd.

Terminated

A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (ATLAS)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States, Israel, Russian Federation, Georgia, Bulgaria, Estonia, Latvia, Poland, Serbia, Ukraine
Pfizer

Active, not recruiting

A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer (CREST)

Non-muscle Invasive Bladder Cancer

China, United States, Spain, Belgium, Korea, Republic of, Australia, United Kingdom, Japan, France, Germany, Canada, Russian Federation, Poland, Italy

Clinical Trials on Non-invasive Inflammatory Markers in Russian Federation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations